Artigo Acesso aberto Revisado por pares

Efficacy of Chemotherapy in BRCA1/2 Mutation Carrier Ovarian Cancer in the Setting of PARP Inhibitor Resistance: A Multi-Institutional Study

2013; American Association for Cancer Research; Volume: 19; Issue: 19 Linguagem: Inglês

10.1158/1078-0432.ccr-13-1262

ISSN

1557-3265

Autores

Joo Ern Ang, Charlie Gourley, C. Bethan Powell, Hilda High, Ronnie Shapira‐Frommer, Vincent Castonguay, Jacques De Grève, Tina Atkinson, Timothy A. Yap, Shahneen Sandhu, Susana Banerjee, Lee-may Chen, Michael Friedlander, Bella Kaufman, Amit M. Oza, Ursula A. Matulonis, Louise J. Barber, Iwanka Kozarewa, Kerry Fenwick, Ioannis Assiotis, James Campbell, Lina Chen, Johann S. de Bono, Martin Gore, Christopher J. Lord, Alan Ashworth, Stan B. Kaye,

Tópico(s)

Ovarian cancer diagnosis and treatment

Resumo

Preclinical data suggest that exposure to PARP inhibitors (PARPi) may compromise benefit to subsequent chemotherapy, particularly platinum-based regimens, in patients with BRCA1/2 mutation carrier ovarian cancer (PBMCOC), possibly through the acquisition of secondary BRCA1/2 mutations. The efficacy of chemotherapy in the PARPi-resistant setting was therefore investigated.

Referência(s)